WBI Investments LLC Purchases New Stake in DexCom, Inc. (NASDAQ:DXCM)

WBI Investments LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,177 shares of the medical device company’s stock, valued at approximately $302,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Capital Research Global Investors grew its position in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after buying an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC grew its holdings in shares of DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Capital World Investors increased its holdings in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after buying an additional 5,256,092 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of DexCom during the 4th quarter valued at $540,178,000. 97.75% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,102 shares of company stock worth $755,103. Corporate insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of DXCM traded up $2.58 during midday trading on Thursday, reaching $113.37. The stock had a trading volume of 1,088,363 shares, compared to its average volume of 2,881,725. The company has a market capitalization of $45.08 billion, a price-to-earnings ratio of 71.48, a price-to-earnings-growth ratio of 2.71 and a beta of 1.16. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company’s 50-day moving average is $120.10 and its 200 day moving average is $125.12.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. On average, equities analysts predict that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on DXCM shares. Citigroup increased their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Redburn Atlantic began coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Raymond James raised their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $140.33.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.